Andere talen Inhibikase Therapeutics, Inc.

Aandelen

IKT

US45719W2052

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 21-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,4 ^USD	-2,10%		-0,71%	+10,24%

17/06	Inhibikase Therapeutics voltooit de registratie van de Fase 2-studie 201? Onderzoek naar Risvodetinib in onbehandelde ziekte van Parkinson	CI
05/06	Inhibikase Therapeutics, Inc. kondigt uitbreiding van zijn therapeutische pijplijn aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinson s disease	18/06
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease	17/06
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease	17/06
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs	05/06
Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline	05/06
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million	20/05
Inhibikase Therapeutics, Inc. announced that it expects to receive $7.999999 million in funding	20/05
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity	16/05
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement	15/05
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension	09/05
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	09/05
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	18/04
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03/04
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03/04
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501	27/03
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity	27/03
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	07/03
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	07/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Inhibikase Therapeutics, Inc.

Aandelen

IKT

US45719W2052

Andere talen

Filters